Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Legislation
|
Business
|
Products
|
Generics
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Pfizer to bolster rare disease portfolio with FoldRx acquisition
02 September 2010
Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make ...
 
India throws rule book at 'superbug' scientists
02 September 2010
Indian physicians who were involved in the controversial "superbug" NDM-1 study that was published in Lancet Infectious Diseases last month have been asked to confirm whether they followed various national guidelines and procedures required for the transfer of biomedical material outside the ...
US judge denies Sanofi-Aventis's bid to stop generic rival for Lovenox
31 August 2010
A federal judge has denied Sanofi-Aventis 's request for a preliminary injunction that would have directed the US FDA to suspend and withdraw its approval of a generic version of Lovenox (enoxaparin sodium) from Sandoz (Novartis) and partner Momenta Pharmaceuticals, which has been on the market for ...
 
Meda to acquire US speciality pharma firm for $350 million
31 August 2010
Meda of Sweden is to acquire the US speciality pharma company Alaven Pharmaceutical to enhance its US marketing capabilities and expand its therapeutic focus to include both gastroenterology and women's health, areas it already operates in outside of the US. Alaven also has an OTC portfolio that ...
Genzyme snubs offer from Sanofi-Aventis
31 August 2010
After months of speculation Sanofi-Aventis, the French pharma major, at the weekend unveiled an all-cash $69.00 a share bid for Genzyme, which values the US biotech at about $18.5 billion. Not surprisingly, the Genzyme board unanimously rejected the offer claiming it to be "an opportunistic ...
 
US judge denies Sanofi-Aventis's bid to stop generic rival for Lovenox
31 August 2010
A federal judge has denied Sanofi-Aventis 's request for a preliminary injunction that would have directed the US FDA to suspend and withdraw its approval of a generic version of Lovenox (enoxaparin sodium) from Sandoz (Novartis) and partner Momenta Pharmaceuticals, which has been on the market for ...
Hikma's US generics sales drive first half
26 August 2010
Hikma Pharmaceuticals of Jordan says its strategy of expansion and diversification has led to it reporting an increase in revenue for the first half ended 30 June to $357.7 million (+11%) and a rise in adjusted operating profit to $73.2 million (+20%). Hikma launched 70 products in various markets ...
 
EXPERT VIEW
Asia Beat: Debate drags on as Taiwan gets its NHI house in order
01 September 2010
Ian Haydock
Taiwan's efforts to reform its financially struggling national health insurance (NHI) scheme go ...

2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010

Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and ...

2010 Scrip 100 - Changes pharma can believe in?
23 August 2010

Ian Schofield picks some of the most significant developments in the health policy and regulation ...

Rare diseases in the Middle East: prospects for CROs
28 July 2010

The treatment of rare diseases in Europe has been significantly enhanced by the EU's Orphan Drug ...

Value-based pricing: Who should set drug prices in the UK?
11 August 2010
While the UK's NHS and pharma sector ponder who may end up negotiating drug prices in light of a ...

Calling German and Spanish Physicists: the EMA Needs You
13 July 2010
Maureen Kenny
German or Spanish physicists hoping for a career change involving a move to London at the end of ...

GW high on pipeline of cannabis extracts
23 August 2010
Katie McQue
GW Pharma has enjoyed recent success with its cannabinoid extract product Sativex (nabiximols), ...

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm